Publications by authors named "Ute Hoch"

Claim this Profile
D
Discovery of Novel, Potent, Orally Bioavailable and Efficacious, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Hematopoietic Stem Cell Mobilization.
Min Wu, Dennis C Koester, Gail Walkinshaw, Danny Ng, Xiaoti Zhou, Ute Hoch

J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Ute Hoch

Eur Urol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.
Debu Tripathy, Sara M Tolaney, Andrew D Seidman, Carey K Anders, Nuhad Ibrahim, Ute Hoch

JAMA Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Ute Hoch

J Immunother Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Adi Diab, Scott S Tykodi, Gregory A Daniels, Michele Maio, Brendan D Curti, Ute Hoch

J Clin Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, Patrick Hwu, Vassiliki Papadimitrakopoulou, Ute Hoch

Cancer Discov· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8 T cell responses capable of curing multi-focal cancer.
Joshua M Walker, Annah S Rolig, Deborah H Charych, Ute Hoch, Melissa J Kasiewicz

J Immunother Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Abuse Potential of Oral NKTR-181 in Recreational Opioid Users: A Randomized, Double-Blind, Crossover Study.
Xue Ge, Jack E Henningfield, Suresh Siddhanti, Janet Jobes, Lin Lu, Ute Hoch

Pain Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Meenu Sharma, Hiep Khong, Faisal Fa'ak, Salah-Eddine Bentebibel, Louise M E Janssen, Ute Hoch

Nat Commun· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
Salah-Eddine Bentebibel, Michael E Hurwitz, Chantale Bernatchez, Cara Haymaker, Courtney W Hudgens, Ute Hoch

Cancer Discov· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.
Hope S Rugo, Javier Cortes, Ahmad Awada, Joyce O'Shaughnessy, Chris Twelves, Ute Hoch

Clin Cancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
Sherwin K B Sy, Yen Lin Chia, Toufigh Gordi, Ute Hoch, Michael A Eldon

Cancer Chemother Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
Heinz-Josef Lenz, Philip Philip, Mark Saunders, Tatjana Kolevska, Kalyan Mukherjee, Ute Hoch

Cancer Chemother Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Javier Cortés, Hope S Rugo, Ahmad Awada, Chris Twelves, Edith A Perez, Ute Hoch

Breast Cancer Res Treat· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Deborah Charych, Samira Khalili, Vidula Dixit, Peter Kirk, Thomas Chang, Ute Hoch

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Javier Cortés, Hope S Rugo, Ahmad Awada, Chris Twelves, Edith A Perez, Ute Hoch

Breast Cancer Res Treat· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Chris Twelves, Javier Cortés, Joyce O'Shaughnessy, Ahmad Awada, Edith A Perez, Ute Hoch

Eur J Cancer· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.
S Kenneth Sy, Theresa D Sweeney, Chunmei Ji, Ute Hoch, Michael A Eldon

Cancer Chemother Pharmacol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.
Javier Cortés, Hope S Rugo, Chris Twelves, Ahmad Awada, Edith A Perez, Ute Hoch

Springerplus· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
Deborah H Charych, Ute Hoch, John L Langowski, Steve R Lee, Murali K Addepalli

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
Edith A Perez, Ahmad Awada, Joyce O'Shaughnessy, Hope S Rugo, Chris Twelves, Ute Hoch

Lancet Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
Chris E Adkins, Mohamed I Nounou, Tanvirul Hye, Afroz S Mohammad, Tori Terrell-Hall, Ute Hoch

BMC Cancer· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Ute Hoch, Carl-Michael Staschen, Randall K Johnson, Michael A Eldon

Cancer Chemother Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Ahmad Awada, Agustin A Garcia, Stephen Chan, Guy H M Jerusalem, Robert E Coleman, Ute Hoch

Lancet Oncol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Gayle S Jameson, John T Hamm, Glen J Weiss, Carlos Alemany, Stephen Anthony, Ute Hoch

Clin Cancer Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis